jcp conference-coverage

Conference Coverage

Precision Medicine and Value-Based Payment in Oncology

03/05/2022

A session at the ACCC 48th Annual Meeting and Cancer Center Business Summit convened industry experts to discuss innovations and obstacles in precision medicine and value-based payment in oncology.

A session at the ACCC 48th...

03/05/2022

Journal of Clinical Pathways

Conference Coverage

Making the Business Case for Comprehensive Cancer Care Services

03/05/2022

Janelle Bradley ;

The President’s Panel at the ACCC 48th Annual Meeting and Cancer Center Business Summit discussed the innovative care models with demonstrable return on investment required for the delivery of high-impact comprehensive cancer care services.

The President’s Panel at the...

03/05/2022

Journal of Clinical Pathways

Conference Coverage

Reconfiguration and Consolidation Trends and Their Impact on Oncology

03/05/2022

Janelle Bradley ;

A session at the ACCC 48th Annual Meeting and Cancer Center Business Summit brought together consultants and leaders to discuss industry reconfiguration and consolidation trends and their impact on oncology.

A session at the ACCC 48th...

03/05/2022

Journal of Clinical Pathways

Conference Coverage

New Tools to Improve Clinical Decision Making and Patient Support

03/05/2022

Marta Rybczynski ;

A session at the ACCC 48th Annual Meeting and Cancer Center Business Summit brought on a panel showcasing products and services that improve clinical making and patient support, featuring platforms from Elsevier, GE Medical, Flatiron Assist,...

A session at the ACCC 48th...

03/05/2022

Journal of Clinical Pathways

Conference Coverage

Cost-Effectiveness of Lisocabtagene Maraleucel vs Axicabtagene Ciloleucel for Relapsed or Refractory LBCL

12/16/2021

Marta Rybczynski ;

Lisocabtagene maraleucel may be cost-effective vs axicabtagene ciloleucel for relapsed or refractory LBCL from a commercial US payer perspective, according to a study presented at 2021 ASH Annual Meeting.

Lisocabtagene maraleucel may be...

12/16/2021

Journal of Clinical Pathways

Conference Coverage

First-Line Venetoclax Plus Azacitidine vs Intensive Chemotherapy for Patients With AML in the Real-World Setting

12/11/2021

Janelle Bradley ;

In the real-world setting, use of intensive chemotherapy was more common than venetoclax plus azacitidine for patients aged 60-75 years with AML.

In the real-world setting, use...

12/11/2021

Journal of Clinical Pathways

Conference Coverage

Real-World Treatment Patterns and Decision-Making for Patients With MM in the United States

12/08/2021

Janelle Bradley ;

Study results presented at the 2021 ASH Annual Meeting provided valuable real-world data on current treatment patterns and decision-making for patients with MM.

Study results presented at the...

12/08/2021

Journal of Clinical Pathways

Conference Coverage

Safety and Cost-Effectiveness of CAR-T Therapy in the Outpatient vs Inpatient Setting

12/08/2021

Janelle Bradley ;

Study findings presented at the 2021 ASH Annual Meeting demonstrate the feasibility and cost-effectiveness of outpatient administration of CAR-T therapy for patients with hematologic malignancies.

Study findings presented at the...

12/08/2021

Journal of Clinical Pathways

Conference Coverage

Real-World Safety, Efficacy of Belantamab Mafodotin for Relapsed/Refractory MM

12/08/2021

Janelle Bradley ;

In the real-world setting, belantamab mafodotin demonstrates comparable responses and toxicities in patients with MM to those seen in clinical trials.

In the real-world setting,...

12/08/2021

Journal of Clinical Pathways

Conference Coverage

Real-World Incidence of Thromboembolic Events in Patients With Metastatic Breast Cancer Treated With Ribociclib

12/07/2021

Janelle Bradley ;

Study findings show patients with metastatic breast cancer treated with ribociclib plus aromatase inhibitors or fulvestrant are not at higher risk for thromboembolic events.

Study findings show patients...

12/07/2021

Journal of Clinical Pathways

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Conference Coverage

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products